EU OKs $5.2B Watson-Actavis Tie-Up
Watson's proposed takeover of Actavis would create the third-largest generic pharmaceuticals company in the world with about $8 billion in revenue, and would expand Watson's reach into Russia and Central and Eastern Europe.
The European Commission investigated the possible impacts of the merger on various drugs including antidepressants...
Already a subscriber? Click here to login